-
: Advanced molecular and protein analysis Mass spectrometry-based imaging Multi-omics technologies Preclinical cardiometabolic animal models They will also gain professional development in data stewardship
-
production processes and are actively exploring the incorporation of new materials, technologies and designs in their operations to achieve zero-carbon construction elements. The construction industry is under
-
their properties, as well as develop ways to manipulate and advance the nano-assembly processes. You would also be involved in scale-up on roll-to-roll pre-pilot kit, to explore applications for these advanced
-
also throughout the development phase, which involves transforming a molecule into a medicine and addressing various chemistry, manufacturing, and control (CMC) challenges. A key aspect of this process
-
advanced materials processing. Closing date for applications: 2 Dec 2025 with interviews shortly afterwards. Stipend: Full funding for 4 years covering a personal maintenance stipend starting at £20,780
-
transformations, and advanced materials processing. Closing date for applications: 2 Dec 2025 with interviews shortly afterwards. Stipend: Full funding for 4 years covering a personal maintenance stipend starting
-
scholarships or funding schemes. Students will not be allowed to supplement fees via self-funding. Application process: Please click on the 'Apply' button above to apply for a PhD in Biochemistry via
-
. Please note: while funding is available to cover this position, applicants are also welcome to apply for other scholarships during the application process. Eligibility We welcome applications from both UK
-
be made after the First Deadline. Fixed-term: The funds for this post are available for 3.5 years in the first instance. Please direct any queries to nanodtc.admin@phy.cam.ac.uk Please quote reference
-
to identify post-translational modifications (PTMs) on FOXA1 that are critical for its ability to cause tumour growth and metastasis, with the goal of finding novel ways of therapeutically blocking FOXA1